ABSTRACT
This study was done in a trial to understand how estrogen performs its antiosteoporotic action. Twenty six postmenopausal women and twenty premenopausal women were included in the study. We measured serum estradiol, interleukin 6 (IL-6) and osteocalcin. We found a highly significant difference in serum estradiol and IL-6 between the two groups. In postmenopausal group, there was a negative significant correlation between estradiol level and both IL-6 and osteocalcin levels. Also there was a significant positive correlation between serum osteocalcin and IL-6. For the premenopausal group of patients there was no significant correlation between any of the parameters. When correlating the parameters of all the 46 patients, there was a highly negative significant correlation between estradiol level and IL-6 and a negative significant correlation between estradiol level and osteocalcin, while there was a positive significant correlation between osteocalcin and IL-6. We can conclude that estrogen exerts its antiosteoporotic effect by modulating the production of IL-6, thus inhibiting its stimulatory effect on osteoblasts.
Subject(s)
Estradiol/analysis , Interleukin-6/analysis , Osteoporosis, Postmenopausal/diagnosis , Adult , Aged , Egypt , Estradiol/blood , Estrogens , Female , Humans , Interleukin-6/blood , Middle AgedABSTRACT
Cyclic GMP contents of the thyroid gland and ovary were significantly increased in response to single and multiple treatments of bromocriptine, an effect which was antagonized by sulpiride. Liver and adrenocortical cyclic GMP levels have not been changed by bromocriptine although sulpiride alone induced a significant reduction. The data may indicate the presence of D2 receptors in ovary and thyroid gland that are related to cyclic GMP.
